biolog
function
bovin
colostr
immunoglobulin
provid
newborn
calf
adequ
passiv
immun
protect
microbi
infect
immunoglobulin
prepar
design
farm
anim
commerci
avail
colostrumbas
product
market
also
human
dietari
supplement
concentr
specif
antibodi
certain
pathogen
microorgan
rais
colostrum
milk
immun
cow
pathogen
antigen
advanc
biosepar
chromatograph
techniqu
made
possibl
fraction
enrich
antibodi
formul
socal
hyperimmun
colostr
milk
prepar
efficaci
prevent
treatment
variou
microbi
infect
evalu
numer
studi
immun
milk
prepar
proven
effect
prophylaxi
infect
caus
varieti
gastrointestin
pathogen
therapeut
efficaci
howev
seem
limit
commerci
immun
milk
product
alreadi
market
applic
expect
come
year
articl
review
recent
progress
made
isol
techniqu
bovin
immunoglobulin
applic
colostr
immun
milk
prepar
fight
variou
microbi
infecti
diseas
human
r
immunoglobulin
ig
togeth
lactoferrin
lactoperoxidas
lysozym
form
import
antimicrobi
system
bovin
lacteal
secret
ig
antibodi
synthes
mammal
respons
antigen
immunogen
stimuli
bacteria
virus
thu
provid
protect
microbi
infect
bovin
colostrum
rich
sourc
ig
also
confer
passiv
immun
newborn
develop
immun
system
review
see
liliu
marnila
ig
specif
antibodi
activ
increas
lacteal
secret
target
hyperimmun
protocol
use
vaccin
contain
inactiv
pathogen
microbi
materi
ig
activ
desir
increas
pool
antibodi
enrich
concentrationfraction
techniqu
lead
product
ig
product
contain
high
antibodi
concentr
titr
prepar
may
find
benefici
applic
human
anim
healthcar
wellb
prevent
infect
control
diseas
review
see
kelli
korhonen
marnila
gill
liliu
marnila
review
focus
current
largescal
technolog
employ
produc
specif
ig
product
clinic
studi
undertaken
determin
efficaci
human
anim
infect
biolog
function
ig
bovin
milk
colostrum
protect
mammari
gland
pathogen
provid
calf
immunolog
protect
surround
pathogen
igg
class
antibodi
compris
total
ig
gl
earli
bovin
colostrum
milk
first
day
parturit
elfstrand
paulsson
nyberg
kesson
tabl
thereaft
ig
content
decreas
sharpli
next
day
tabl
case
serum
antibodi
igg
antibodi
igg
domin
ig
class
colostrum
multitud
function
includ
opson
complement
fixat
prevent
adhes
pathogen
microb
endotheli
line
inhibit
bacteri
metabol
block
enzym
agglutin
bacteria
neutral
toxin
virus
marnila
korhonen
igm
antibodi
produc
smaller
amount
igg
consider
effici
igg
abovement
activ
especi
complement
fixat
remain
obscur
signific
mechan
milk
colostrum
contrast
secretori
iga
fix
complement
opson
bacteria
agglutin
antigen
neutral
virus
bacteri
toxin
prevent
adhes
enteropathogen
bacteria
mucos
epitheli
cell
marnila
korhonen
although
publish
scientif
literatur
contain
substanti
amount
inform
method
technolog
use
isol
extract
concentr
purif
ig
milkcolostrum
report
method
suitabl
largescal
product
ig
techniqu
potenti
scale
describ
review
rapid
develop
new
chromatograph
membranesepar
technolog
last
year
possibl
isol
individu
milk
protein
largescal
kelli
mcdonagh
korhonen
mauboi
number
marnila
korhonen
elfstrand
et
al
data
extract
korhonen
pilotor
industrialscal
method
isol
purif
ig
colostr
chees
whey
base
membranesepar
koth
dichtelmullar
stephan
echentopf
stott
luca
membranesepar
chromatograph
techniqu
bottomley
korhonen
vasara
kosunen
marnila
patent
recoveri
rate
ig
use
method
vari
level
present
start
materi
thoma
cordl
criswel
westfal
barefoot
develop
process
select
enrich
ig
whey
filtrat
formedinplac
membran
sinter
stainlesssteel
tube
process
employ
size
exclus
protein
charg
manipul
around
isoelectr
point
protein
select
reject
pass
compon
stream
igg
chees
whey
enrich
total
whey
protein
recoveri
igg
recent
baruah
belfort
use
predict
aggreg
transport
model
microfiltr
mm
pore
size
membran
transgen
goat
milk
helic
hollowfibr
modul
oper
low
uniform
transmembran
pressur
low
permeat
flux
rate
permeat
cocurr
flow
increas
yield
ig
permeat
less
similarli
microfiltr
mm
membran
poros
combin
ultrafiltr
uf
membran
cutoff
kda
bovin
equin
caprin
colostrum
result
least
recoveri
igg
microfiltr
iggt
puriti
subsequ
ultrafiltr
piot
fauquant
madec
mauboi
mehra
kelli
also
produc
igrich
fraction
microfiltr
chees
whey
use
tubular
ceram
membran
mm
pore
size
ig
protein
ratio
fraction
approxim
time
origin
chees
whey
membranesepar
milkcolostr
whey
ig
result
high
puriti
recoveri
ig
fraction
specif
chromatograph
techniqu
appli
improv
yield
puriti
ig
prepar
may
easili
scaledup
igg
isol
whey
immobil
metalaffin
chromatographi
imac
uf
concentr
whey
appli
imac
column
load
copper
igg
fraction
puriti
chees
whey
fukumoto
lichan
kwan
nakai
acid
cheddar
chees
whey
respect
almashikhi
lichan
nakai
isol
immunoaffin
chromatographi
method
suitabl
isol
pure
igg
subclass
igg
igg
cheddar
chees
whey
colostrum
report
akita
lichan
immunoaffin
column
made
specif
egg
yolk
igi
rais
bovin
igg
igg
milk
free
either
igg
subclass
success
produc
select
remov
igg
igg
subclass
techniqu
expand
bed
adsorpt
chromatographi
ebac
appli
isol
ig
whey
nielsen
oland
lihm
use
adsorb
tailor
ligand
chemistri
ebac
provid
signific
advantag
convent
pack
bed
column
chromatographi
decis
characterist
adsorb
media
expand
column
upward
flow
liquid
appli
allow
free
passag
particul
impur
feed
stream
column
thu
allow
crude
nonclarifi
feed
appli
column
ig
puriti
achiev
method
first
industri
implement
ebac
dairi
industri
carri
separ
whey
protein
dairi
farmer
australia
whey
manufactur
process
acid
rennet
treatment
shown
reduc
antigen
escherichia
coli
specif
antibodi
activ
assay
use
elisa
whole
skim
colostr
igg
iga
igm
ando
et
al
probabl
loss
antibodi
activ
whey
prepar
due
involv
ig
casein
precipit
extent
decreas
lower
whey
product
skim
colostrum
whole
colostrum
addit
rennet
whey
retain
antibodi
activ
manufactur
acid
whey
igg
antibodi
activ
resist
heat
treatment
less
stabl
whole
skim
colostrum
skim
colostr
whey
hand
igm
activ
colostrumderiv
fraction
reduc
heat
treatment
without
signific
differ
fraction
howev
siga
antigenspecif
antibodi
activ
suscept
whey
prepar
process
heat
treatment
igg
igm
activ
heat
stabil
markedli
lower
whole
colostrum
colostrumderiv
fraction
use
enzymelink
immunosorb
assay
elisa
radial
immunodiffus
rid
techniqu
igg
concentr
antigenbind
activ
igg
lipopolysaccharid
fp
fraction
bacteria
e
coli
e
coli
salmonella
flexneri
enteritidi
typhimurium
measur
commerci
heattreat
fluid
milk
lichan
kummer
losso
kit
makai
establish
milk
heat
treatment
batch
pasteur
min
destroy
specif
antigenbind
activ
igg
hightemperatur
shorttim
htst
led
loss
igg
concentr
similar
reduct
antigenbind
activ
hand
ultrahigh
temperatur
uht
treatment
denatur
concentr
antigenbind
activ
igg
contrast
mainer
ena
calvo
report
bovin
milk
ig
could
resist
htst
pasteur
treatment
without
affect
structur
igg
iga
igm
concentr
denatur
milk
sampl
heat
glass
capillari
temperaturecontrol
water
bath
denatur
igg
determin
use
rid
similar
studi
mainer
dominguez
randrup
sanchez
calvo
also
show
htst
pasteur
littl
effect
activ
bovin
colostr
igg
origin
rotaviru
neutral
activ
reduc
puls
electr
field
pef
emerg
nontherm
technolog
altern
thermal
process
report
inactiv
microorgan
highintens
electr
field
contribut
thermal
effect
minim
zhang
molsalvegonzalez
barbosacanova
swanson
pef
treatment
purifi
bovin
igg
solut
buffer
caus
detect
chang
secondari
structur
immunoact
igg
measur
circular
dichroism
cd
li
bomser
zhang
effect
freezedri
microwav
vacuum
evapor
spraydri
colostrum
colostr
ig
antigenspecif
antibodybind
activ
report
chelack
morley
hain
total
colostr
ig
measur
rid
antigenspecif
antibodybind
activ
parainfluenza
type
viru
bovin
viral
diarrhoea
viru
bovin
respiratori
syncyti
viru
infecti
bovin
rhinotrach
viru
analys
elisa
ig
content
colostrum
larg
retain
dehydr
method
investig
retent
result
evalu
control
dri
colostrum
stabil
antigenspecif
antibodi
function
show
microwav
vacuum
evapor
caus
greatest
loss
biolog
activ
follow
freezedri
spraydri
spray
dri
effici
fast
costeffect
dehydr
method
maintain
bioactiv
ig
bovin
igg
isol
chees
whey
membran
steril
asept
ad
carton
uhttreat
milk
fukumoto
skura
nakai
concentr
ad
bovin
igg
stabl
month
storag
milk
differ
temperatur
freez
storag
frozen
storag
lyophil
colostrum
least
year
detriment
effect
ig
antibodi
activ
campylobact
jejuni
determin
elisa
husu
et
al
bacteri
ferment
milk
yoghurt
probiot
bacterium
lactobacillu
rhamnosu
gg
significantli
reduc
biolog
activ
ad
colostr
antibodi
streptococcu
mutan
wei
marnila
korhonen
antibodi
activ
ferment
immun
milk
maintain
storag
day
current
commerci
ig
product
prepar
colostrum
nonvaccin
immun
cow
colostrum
collect
defat
pasteur
condit
retain
biolog
activ
dri
product
form
spray
dri
freezedri
powder
filter
colostrum
whey
liquid
concentr
dri
product
includ
whole
colostrum
powder
skim
powder
skim
colostrum
protein
concentr
colostrum
whey
concentr
possibl
list
everi
conceiv
ig
ingredientproduct
commerci
avail
global
market
potenti
health
promot
ig
ingredi
properietari
develop
clinic
investig
tabl
list
commerci
ig
product
describ
literatur
pakkanen
aalto
scammel
gastrogardr
tm
hyperimmun
antirotaviru
colostrum
concentr
launch
australia
pharmaceut
product
prevent
rotaviru
diarrhoea
infant
young
children
davidson
daniel
nunan
moor
whyte
davidson
tam
kirubakaran
intact
tm
colostrum
concentr
nonhyperimmun
cow
shown
effect
run
row
perform
buckley
abbott
martin
brinkworth
whyte
buckley
et
al
biotest
pharm
gmbh
germani
produc
lactimmunoglobulin
biotest
colostrum
product
nonimmun
cow
human
use
test
treatment
sever
diarrhoea
aid
patient
stephan
dichtelmul
lissner
viabl
bioproduct
ltd
finland
produc
bioenervi
tm
sterilefilt
colostrum
product
provid
growth
archibald
new
ig
product
continu
introduc
commerci
market
specif
healthcar
sector
tabl
like
ig
concentr
antibodi
specif
also
vari
significantli
milk
colostrum
differ
cow
depend
spectr
antigen
encount
anim
lifetim
colostra
milk
contain
detect
amount
natur
antibodi
enterobacteria
like
e
coli
presenc
antibodi
antigen
predict
korhonen
et
al
kelli
antibodi
titr
certain
pathogen
virul
factor
rais
sever
hundr
time
immun
cow
microbi
vaccin
parturit
immun
colostrum
result
immun
regim
fundament
differ
properti
efficaci
pathogen
normal
colostrum
two
concept
therefor
differenti
emphas
fact
present
normal
colostrum
prepar
made
mani
countri
regard
food
dietari
supplement
wherea
colostr
prepar
immun
cow
often
regard
pharmaceut
regulatori
statu
remain
defin
low
ph
gastric
acid
significantli
reduc
activ
bovin
milk
ig
concentr
milk
ig
degrad
human
gi
tract
f
ab
fab
fc
fragment
intestin
proteolyt
enzym
pepsin
trypsin
chymotypsin
carboxypeptidas
elastas
review
see
reilli
domingo
sandhu
howev
result
f
ab
fab
fragment
retain
natur
activ
oral
caviti
oesophagu
least
part
neutral
adhes
inhibit
activ
intestin
ml
whole
milk
supplement
immun
colostrum
contain
rotaviru
antibodi
administ
children
time
day
day
rotaviru
antibodi
activ
detect
elisa
faecal
specimen
obtain
studi
pacyna
et
al
secretori
piec
compon
iga
molecul
make
siga
resist
proteolyt
digest
enzym
ig
class
reilli
et
al
surviv
igg
increas
encapsul
gelatin
kelli
et
al
last
year
larg
number
clinic
studi
carri
human
anim
order
establish
efficaci
immun
milk
prepar
studi
review
mani
recent
articl
kelli
korhonen
et
al
liliu
marnila
articl
recent
studi
review
bovin
milk
antibodi
studi
local
passiv
immun
prevent
dental
cari
review
see
koga
oho
shimazaki
nakano
sinc
human
immun
activ
cari
bacteria
due
risk
side
effect
adher
princip
cari
pathogen
streptococcu
mutan
crucial
factor
colon
oral
caviti
recent
studi
bovin
colostr
ig
shown
specif
block
bacteri
colon
factor
cow
immun
proper
bacteri
structur
mitoma
et
al
prepar
fusion
salivabind
alaninerich
region
cell
surfac
protein
antigen
pac
glucanbind
domain
glucosyltransferasei
cell
surfac
protein
str
mutan
immun
cow
fusion
immun
milk
prepar
made
colostrum
cow
prove
effect
prevent
dental
cari
develop
experiment
rat
model
given
concentr
day
day
shimazaki
et
al
examin
effect
immun
milk
contain
antibodi
mention
fusion
protein
adult
subject
antibiot
cetylpyridinium
chlorid
treatment
immun
milk
inhibit
significantli
recolon
str
mutan
saliva
plaqu
compar
control
group
also
ratio
str
mutan
total
streptococci
saliva
plaqu
immun
milk
group
lower
control
group
studi
support
observ
loimaranta
et
al
immun
milk
cow
immun
str
mutan
str
sobrinu
whole
cell
vaccin
inhibit
vitro
glucosyltransferas
fructosyltransferas
activ
str
mutan
inhibit
adher
bacteria
salivaco
hydroxyapatit
particl
promot
aggreg
str
mutan
loimaranta
et
al
use
mouth
rins
day
immun
prepar
result
higher
rest
ph
dental
plaqu
adult
compar
control
group
loimaranta
et
al
rel
number
mutan
streptococci
decreas
significantli
immun
product
rins
period
compar
control
thu
rins
bovin
immun
whey
indic
favour
effect
human
dental
plaqu
control
str
mutan
human
oral
caviti
wei
et
al
supplement
pasteur
milk
immun
prepar
ferment
milk
lactobacillu
rhamnosu
gg
atcc
lgg
probiot
bacteria
earlier
shown
reduc
cari
risk
day
care
children
ad
milk
et
al
decreas
salivari
str
mutan
count
adult
subject
administ
chees
ahola
et
al
immun
prepar
prevent
growth
lgg
milk
ferment
specif
antibodi
synergist
str
mutan
adhes
inhibit
effect
lgg
vitro
lggferment
uhttreat
milk
activ
ad
anticari
antibodi
maintain
expect
shelflif
product
anticariogen
point
view
may
benefici
add
bovinespecif
antibodi
mutan
streptococci
probiot
lggcontain
milk
product
recent
studi
colostr
specif
ig
cow
immun
whole
cell
helicobact
feli
protect
mice
experiment
h
feli
infect
marnila
et
al
treatment
specif
colostr
ig
report
reduc
degre
gastric
inflamm
helicobact
colon
mice
casswal
et
al
marnila
et
al
degre
inflamm
children
oona
et
al
studi
suggest
ingest
live
lactic
acid
bacteria
suppress
h
pylori
infect
sykora
et
al
wang
et
al
thu
synergist
therapeut
effect
could
achiev
combin
ig
probiot
bacteria
hori
et
al
recent
design
yoghurt
drink
contain
lb
acidophilu
bifidobacteria
spp
ad
egg
yolk
igi
hen
immun
h
pylori
ureas
enzym
pathogen
factor
h
pylori
yoghurt
similarli
abovedescrib
bovin
colostr
igg
sour
milk
egg
yolk
igi
antibodi
remain
stabl
activ
yoghurt
week
clinic
studi
administ
ml
igyyogurt
time
daili
week
h
pylori
posit
subject
decreas
significantli
urea
breath
test
valu
indic
decreas
vivo
activ
ureas
enzym
compar
control
group
bovin
colostr
ig
cow
immun
e
coli
ferric
citrat
receptor
recent
shown
abl
inhibit
iron
uptak
strain
mastit
isol
e
coli
takemura
hogan
smith
effect
iron
deplet
igg
test
growth
e
coli
strain
result
suggest
colostr
igg
inhibit
iron
uptak
growth
vitro
littl
effect
growth
fedeplet
media
takemura
hogan
smith
immun
cow
e
coli
ferric
citrat
receptor
minim
effect
mastiti
follow
intramammari
challeng
e
coli
isol
origin
natur
occur
mastiti
takemura
hogan
lin
smith
ig
enrich
colostrum
product
immulac
tm
made
colostrum
nonimmun
cow
reduc
mortal
mice
due
oral
challeng
enterohaemorrhag
e
coli
funatogawa
et
al
anim
given
colostr
prepar
week
solut
start
h
challeng
bacteria
ig
prepar
prove
effect
inhibit
colon
growth
e
coli
intestin
mice
tawfeek
najim
almashikhi
supplement
caseinbas
babi
formula
colostr
ig
concentr
normal
cow
cow
immun
polyval
five
strain
monoval
e
coli
vaccin
formula
given
infant
daili
g
per
kg
bodi
weight
day
field
trial
iraq
control
group
receiv
either
similar
formula
supplement
normal
colostr
prepar
breastf
infant
receiv
formula
contain
immun
prepar
significantli
lower
incid
diarrhoea
given
formula
contain
control
prepar
month
followup
period
immun
formula
group
number
mean
diarrhoea
episod
control
group
sever
diarrhoea
judg
durat
day
day
averag
immun
formula
control
group
respect
prepar
well
toler
evid
suggest
shigellosi
could
prevent
use
colostr
ig
prepar
cow
immun
certain
sh
flexneri
antigen
review
see
kelli
korhonen
et
al
howev
children
suffer
alreadi
establish
sh
dysenteria
infect
treat
ml
hyperimmun
colostr
prepar
sh
dysenteria
antigen
combin
antibiot
pivmecillinam
three
time
per
day
day
differ
found
clinic
paramet
compar
patient
treat
control
prepar
antibiot
ashraf
mahalanabi
mitra
tzipori
fuch
suggest
shigellosi
specif
colostr
antibodi
prevent
infect
effect
treatment
alreadi
establish
one
clostridium
difficil
colon
result
often
antibiot
treatment
caus
sever
infecti
diarrhoea
coliti
releas
two
kind
exotoxin
b
hamster
model
ig
prepar
made
bovin
immun
colostrum
cow
immun
c
difficil
toxin
b
shown
effect
treatment
experiment
c
difficil
diarrhoea
kink
william
recent
van
dissel
et
al
use
prepar
made
milk
cow
immun
c
difficil
toxin
whole
cell
c
difficil
support
treatment
week
standard
antibiot
treatment
uncontrol
cohort
studi
nine
patient
histori
relaps
c
difficil
diarrhoea
regimen
one
patient
c
difficil
toxin
disappear
faec
followup
period
month
none
patient
anoth
episod
c
difficil
diarrhoea
earlier
studi
consumpt
milk
protein
thought
lower
cholesterol
peopl
hypercholesterolaemia
risk
factor
cardiovascular
diseas
recent
earnest
jordan
safir
weaver
church
report
placebocontrol
trial
blood
deriv
bovin
ig
fraction
reduc
total
cholesterol
level
mmol
l
mmol
l
mildli
hypercholesterolem
subject
g
administ
daili
week
respect
reduct
mainli
due
decreas
ldl
level
baselin
mmol
l
mmol
l
mechan
effect
remain
unknown
find
encourag
major
surgic
procedur
endotoxemia
acut
phase
reaction
may
occur
due
intestin
endotoxin
reach
bloodstream
transloc
bacteri
product
orth
et
al
treat
patient
day
abdomin
surgeri
either
colostr
prepar
g
daili
four
dose
per
day
oral
lactobin
placebo
singl
shot
antibiot
mezlocillin
metronidazol
lactobin
group
show
lower
level
endotoxin
endotoxin
neutral
capac
blood
placebo
group
author
conclud
colostr
prepar
reduc
endotoxemia
suggest
stabil
gut
barrier
surgeri
anoth
studi
coronari
bypass
patient
given
g
daili
either
bovin
colostr
prepar
placebo
start
day
surgeri
orth
et
al
colostr
prepar
reduc
postop
crplevel
fail
reduc
periop
endotoxemia
known
whether
result
attribut
colostr
ig
neutral
endotoxin
intestin
growth
factor
enforc
gut
barrier
incid
upper
respiratori
infect
adult
male
reduc
oral
administ
colostr
product
intact
tm
brinkworth
buckley
author
suggest
effect
like
caus
indigen
growth
factor
present
colostrum
ig
consider
progress
made
isol
enrich
techniqu
immunoglobulin
bovin
colostrum
chees
whey
enabl
develop
commerci
ig
prepar
target
health
promot
farm
anim
human
order
improv
efficaci
prepar
custom
immun
scheme
cow
design
purpos
rais
specif
antibodi
enhanc
specif
antibodi
activ
milk
ig
target
immun
isolationconcentr
technolog
may
futur
remark
potenti
produc
ig
product
human
health
care
part
healthpromot
diet
also
altern
supplement
medic
cure
specifi
human
diseas
clinic
trial
ig
prepar
seldom
caus
undesir
symptom
health
risk
mainli
due
allergen
properti
whey
protein
bernhiselbroadb
yolken
sampson
gingerich
mcphillip
howev
regulatori
statu
product
still
unclear
mani
countri
treat
pharmaceut
case
studi
see
hoerr
bostwick
colostr
milk
ig
prevent
attach
pathogen
epitheli
line
critic
step
establish
infect
thu
oral
administ
bovin
milk
colostr
ig
proven
effect
prevent
oral
mediat
infect
hand
treatment
alreadi
establish
infect
promis
therapeut
effect
report
diseas
infect
maintain
constant
reattach
reinfect
eg
insid
oral
caviti
gi
lumen
toxin
inflammatori
compound
involv
neutral
specif
ig
colostr
prepar
incid
diarrhoea
mortal
rate
high
among
small
children
develop
countri
prevent
diarrhoea
diminish
mortal
also
improv
health
gener
increas
antibiot
resist
among
pathogen
give
emphasi
need
develop
new
mean
prevent
diseas
nutrit
intervent
modul
gi
flora
turn
integr
part
health
promot
also
develop
countri
suggest
combin
bovin
milk
colostr
ig
probiot
lactic
acid
bacteria
could
provid
consider
prospect
health
promot
futur
bioactiv
compon
occur
natur
colostrum
lactoferrin
growth
factor
may
also
synergist
effect
address
gastrointestin
disord
